While Roche is still involved in cancer drugs, it is diversifying into other disease areas and has targeted the haemophilia market with Hemlibra (emicizumab). With this new indication, Hemlibra is ...

Emicizumab (Hemlibra) was approved by the FDA in 2018 to prevent and reduce bleeding for patients who suffer from hemophilia A. The HAVEN 7 trial showed that emicizumab is both safe and effective ...

The launch of Hemlibra (emicizumab) in 2017, with a label expansion in 2018 to broaden its use – had a speedy impact on Eloctate, which also came from Bioverativ's stable. Sanofi recorded a $2 ...